

**University of Texas Health Science Center at San Antonio
Institutional Biosafety Committee (IBC)
Microsoft Teams MINUTES OF MEETING
September 09, 2025**

Members attending the meeting: Bieniek, Kevin; Burgin, Tiffani; Chatterjee, Bandana; Chen, Ching-Kang Jason; Chen, Chun-Liang; Ginsburg, Brett; Mishra, Bibhuti; Paukert, Martin; Prewit, Egle; Salamango, Daniel; Shio, Yuzuru; Vogel, Kristine; Wiederhold, Nathan; Yeh, Chih-Ko; Macias, Dorothy (alternate for Charlton, Michael - voting)

Guests Present: Rincon, Erica; Melendez, Griselda; Barlett, Emily; Vasquez, Rebecca.

Absent members: Charlton, Michael; Dallas, Steven; Dell, Shelbie; Gauduin, Marie Claire; Gould, Georgianna; Martinez-Sobrido, Luis; Xiang, Yan; Bloodworth, Rebecca.

1. Panel Chair Announcement

The meeting was called to order at 11:01 a.m. by the IBC Co-Chair, Dr. Tiffani Burgin. This is the first meeting of FY2026. A quorum was established. The Charge to the Committee was presented by Ms. Dorothy Macias, Biological Safety Manager, Environmental Health & Safety Department.

2. Confidentiality of Panel Proceedings and Conflict of Interest

The members of the panel and the persons employed by the panel shall maintain the confidentiality of the panel's proceedings unless such information is already made available to the public. The Parties shall maintain the confidentiality of the panel's hearings, deliberations, and initial report, and all written submissions to, and communications with, the panel.

Board Members will be reminded of their responsibility to declare any conflicts of interest prior to the discussion of an agenda item. Members will be reminded that in the event they have a conflict of interest (e.g. a member of the research team or is supervised by a member of the research team), the Member with a conflict may be in the meeting room to provide information requested by the IBC but will be asked to leave the meeting room before the final discussion and voting on the protocol with which the IBC Member has a conflict.

3. Approval of minutes from the previous meeting

The Committee approved the minutes as written from the August 12, 2025, IBC meeting.

Approved (16 voted to approve, 0 opposed, 0 abstained)

4. Review of Approved Protocols- The spreadsheet of FY2026 approved protocols will be sent out for review in December 2025.

5. Old Business –

6. Educational Items – None

7. Occupational Medicine- As of September 1, 2025, there were 7 needlesticks, 4 were UT Health

Staff/Employee and 3 were UT students. There were 3 exposures of Bordetella pertussis by UT Health staff. There was one mold exposure by an UT Health employee. There were two exposures to the eye, one was a UT Health employee and the other was an UT student.

8. Other – Chemical Safety-Lab Safety Award Recipients FY 2025

Dr. Morel- Department of Microbiology and Molecular Genetics
 Dr. Hargreaves- Dean of Dental School
 Dr. Tumanov- Department of Microbiology and Molecular Genetics
 Dr. Sander Hacker- Department of LAR
 Dr. Hiroi- Department of Pharmacology
 Dr. Poidevin- Department of Neurosurgery
 Dr. Ikeno- Barshop Institute
 Dr. Kelly Reveles- Department of Pharmacotherapy ED & RSRCH CT
 Dr. Alexander Mazin- Biochemistry and Structural Biology
 Dr. Brett Ginsburg- Psychiatry & Behavioral Sciences

9. Review of EHS Assistant-

10. Meeting Reminder

The next meeting will be held on October 14, 2025.

Protocols for Review

11. Presentation, Discussion, and Voting on a Renewal Protocol:

Protocol ID: 0000019359

Principal Investigator: Brenner, Andrew; Mays Cancer Center

Title: Overcoming CXCL12-mediated resistance in Glioblastoma.

Review Type: Full Committee Review

Form Type: Renewal

Approved (16 voted to approve, 0 opposed, 0 abstained)

Renewal application to work with Lentivirus recombinant deficient, Human brain cells, human cell lines (U87, U251, C6, HEK293s), cancer cells/ tissue, human blood, tissue/body fluids, and vectors (pPackH1, pLKO.1) at BSL-2 containment. Work with E. coli, microRNA, Rat cell lines, Mouse cell lines, vector (pcDNA3.1) at BSL-1 containment.

In vivo:

Work with human cell lines (U87, U251, C6), Cancer cells/tissues, and ID8 in transgenic mice at ABSL-2 containment.

IACUC# IAMEND202400000479

Protocol does include the use of recombinant DNA.

This protocol was approved with clarification

1. The committee requested clarification on biological agents, their source, and the location of the room where the procedures will be utilized, as stated in the summary.

NIH Guidelines:

Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1

Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1

Use of or the cloning of genes from, or into a Risk Group 2, 3, 4 or restricted agent. III-D-1, 2

Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1

Cloning and vector construction in bacteria and yeasts. III-E, III-F

Use of recombinant or synthetic nucleic acid molecules for detection purposes (e.g. probes) III-F

Use of recombinant or synthetic nucleic acid molecule in cultured cells. III-E, III-F

Administration of recombinant or synthetic nucleic acid molecules into animals III-D-4

Experiments involving transgenic/knockout animals requiring ABSL-1 containment. III-E-3

Experiments involving transgenic/knockout animals requiring ABSL-2 and above containment. III-D-4

12. Presentation, Discussion, and Voting on an Amendment Protocol:

Protocol ID: 0000020262

Principal Investigator: Nicholson, Susannah; Surgery

Title: bioTroop: Bioanalyses of the Trauma Resuscitation with Group O Whole Blood Or Products (TROOP) Trial

MATIC-2: Massive Transfusion in Children-2 (MATIC-2)

Rat Microbiome Study: Investigating the Gut Microbiome as a Driver of Trauma-Induced Complications and a Therapeutic Target

Review Type: Full Review

Form Type: Amendment

Approved (16 voted to approve, 0 opposed, 0 abstained)

Amendment application to work with human fecal swabs, human stool samples, and buccal swabs at BSL-2 containment. Work with Rat fecal matter at BSL-1 containment.

In vivo:

Work with rat fecal matter in rats at ABSL-1 containment.

IACUC# IPROTO2024000049

Protocol does not include the use of recombinant DNA.

This protocol was approved as written.

NIH Guidelines:

Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1

13. Presentation, Discussion, and Voting on a Renewal Protocol:**Protocol ID:** 0000020276**Principal Investigator:** Ruparel, Nikita; Endodontics**Title:** N/A**Review Type:** Full Review**Form Type:** Renewal**Approved** (16 voted to approve, 0 opposed, 0 abstained)

Renewal application, to work with *Parvimonas micra*, *Porphyromonas endodontalis*, *Actinomyces naeslundii*, human fibroblasts, Apical papilla, Human cell lines (Jurkat, ThP1-LuciaNF-#B) at BSL-2 containment. Work with AAV, vectors (Edit-R-Cas9 nuclease Protein NLS, MIF crRNA, tracrRNA, Edit-r cr RNA non-targeting, DharmaFECT transfection reagent, AAV-shRNA-CD74) at BSL-1 containment. These will be in storage only: *Enterococcus faecalis*, *Porphyromonas gingivalis*, *Prevotella intermedia*, and *Fusobacterium nucleatum*.

In vivo:

Work with human fibroblasts and Apical papilla in transgenic and knock-out mice at ABSL-1 containment.

IACUC# 20170032AR

Protocol does include the use of recombinant DNA.

This protocol was approved as written.

*NIH Guidelines:**Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1**Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1**Administration of recombinant or synthetic nucleic acid molecules into animals III-D-4**Experiments involving transgenic/knockout animals requiring ABSL-1 containment. III-E-3***14. Presentation, Discussion, and Voting on an Initial Protocol:****Protocol ID:** 0000020340**Principal Investigator:** Shanmugasundaram, Karthigayan; Molecular Medicine**Title:** Targeting METTL3 to Overcome drug resistance in Metastatic clear cell Renal cell carcinoma.**Review Type:** Full Review**Form Type:** Initial**Approved** (16 voted to approve, 0 opposed, 0 abstained)

Initial application, to work with human cell lines (786-O, HK-2, RCC4, A498, Caki-1, ACHN), and PDX tumor fragments at BSL-2 containment. Work with mouse tissue and mouse blood at BSL-1 containment.

In vivo:

Work with human cell line (RCC4) and PDX tumor fragments in mice at ABSL-2 containment.

IACUC# IPROTO202500000074

Protocol does include the use of recombinant DNA.

This protocol was approved as written.

NIH Guidelines:

Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1

Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1

Experiments involving transgenic/knockout animals requiring ABSL-2 and above containment. III-D-4

15. Presentation, Discussion, and Voting on a Renewal Protocol:

Protocol ID: 0000020498

Principal Investigator: Zhao, Weixing; Biochemistry & Structural Biology

NIH Funded: RO1GM141091, RO1CA268641, PO1CA275717

Title: “Genome maintenance via the BRCA-RAD54 Axis.”

“Bladder cancer PD-L1 control of Homologous recombination: Basic mechanisms applied to Novel treatments.”

“Regulation of BRCA-dependent Genome Repair via the 53BP1 Axis.”

Review Type: Full Review

Form Type: Renewal

Approved (16 voted to approve, 0 opposed, 0 abstained)

Renewal application, to work with human cell lines (HELA, HEK293, HEK293T, U2OS, MCF-7, MCF-10a, MDA-MB-436, T47D, DLD1), Lentivirus-shRNA-TR, and vectors (pcDNA3.1, psPAX2, pMD2.G, pTRIPZ) at BSL-2 containment. Work with E. coli (lab strains), E. coli DH5alpha, Insect cell line, Sf9, Bacterial Plasmid DNA, Human cDNA, siRNA, shRNA, rDNA in E. coli, Baculovirus, Saccharomyces cerevisiae, and vectors (pET-11, pET-15b, pET-28a, pET-32, pFastBac) at BSL-1 containment.

Protocol does include the use of recombinant DNA.

This protocol was approved as written.

NIH Guidelines:

Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1

Use of or the cloning of genes from, or into a Risk Group 2, 3, 4 or restricted agent. III-D-1, 2

Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1

Cloning and vector construction in bacteria and yeasts. III-E, III-F

Use of recombinant or synthetic nucleic acid molecules for detection purposes (e.g. probes) III-F

Use of recombinant or synthetic nucleic acid molecule in cultured cells. III-E, III-F

Adjourn: The meeting adjourned at 12:03 P.M.

T. Burgin, PA-C

Dr. Tiffani Burgin
Institutional Biosafety Committee Co- Chair
University of Texas Health San Antonio

Dorothy Macias

Dorothy Macias
Recorder, Institutional Biosafety Committee
University of Texas Health San Antonio

dam